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DOI: 10.1039/c0jm01487gTo generate bioactive coatings for medical implants, a novel procedure has been developed using
a coating of mesoporous silica for controlled drug delivery. Plain glass slides were used as substrates.
The mesoporous coatings were then loaded with the antibacterial drug ciprofloxacin. The drug release
kinetics were investigated in a physiological buffered solution. The drug loading capacity of the
unmodified mesoporous coatings was low but could be increased nearly ten-fold (to about 2 mg cm2 of
the macroscopic surface) by functionalizing the mesoporous surface with sulfonic acid groups. To
achieve a controlled drug release over an extended time period, further coatings were added. Covering
the surface of the drug loaded mesoporous silica layer by dip-coating with bis(trimethoxysilyl)hexane
resulted in an organosiloxane layer which retarded the release for up to 30 days. By an additional
evaporation coating with dioctyltetramethyldisilazane, the release of ciprofloxacin was prolonged for
up to 60 days. The biocompatibility of the different coatings was tested in cell culture assays. The
presence of the additional silane-derived hydrophobic coatings somewhat reduced the
biocompatibility. The antibacterial efficacy of the materials was demonstrated by using clinically
relevant biofilm-forming pathogenic bacteria. A test where the sequential release of ciprofloxacin
(in 2 days intervals) and the bacterial viability were tested in parallel showed good concordance in the
results. The material where a sulfonate-functionalized mesoporous silica layer is loaded with
ciprofloxacin and then coated by an organosiloxane layer derived from bis(trimethoxysilyl)hexane
showed the best results with regard to antibacterial efficacy and will further be tested in animal
experiments.Introduction
Microbial biofilms on clinical implants pose a major clinical
problem which is difficult to treat.1,2 Numerous strategies have
been devised to prevent biofilm formation by coating the implant
surfaces with antimicrobial substances. Mesoporous silica
materials offer a novel opportunity for this purpose. They are
currently being investigated as controlled drug release systems
due to their unique properties as high surface area, tunable pore
size with narrow distribution in the nanometre range and
adaptable surface chemistry based on functionalization of the
silanol groups present on the silica surface. Mesoporous silica
shows a good biocompatibility in animal experiments.3–5
Usually, mesoporous silicas are studied in the form delivered by
solution-phase syntheses, namely as powders, or, in some cases,
as mesoporous hollow silica spheres.6–8 These material forms are,
however, difficult to apply in combination with a pre-formed
implant or prosthesis. For this purpose, mesoporous silica films,
deposited on the surface of the implant, present a promisingaInstitut f€ur Anorganische Chemie, Leibniz Universit€at Hannover,
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752 | J. Mater. Chem., 2011, 21, 752–760practical approach.3–5 For example, ossicular replacement pros-
theses often have to be implanted into an infected middle ear.
These often chronic infections play an important part in the
implantation of alloplastic materials used for ossicular replace-
ment.9,10 Therefore, a systemic antibiotics therapy, which is
stressful for the body, is typically applied after the implantation.
In the ear region, chronic infections are caused primarily by the
difficult pathogen Pseudomonas aeruginosa, which is treatable
with the antibiotic ciprofloxacin. Local delivery of an antibiotic
from the freshly implanted prosthesis will help in combating this
problematic bacterial flora and thus assist in the healing process.
The loading and the release of drugs from mesoporous silica
can be controlled in different ways, as shown in many investi-
gations. In addition to the size and the shape of the pores and
particles,11–13 the chemical interaction of the materials surface
with the drug is the most important factor.14 Silica surfaces can
be equipped with functional residues by grafting, i.e. the post-
synthetic reaction of functionalized silanes with the silanol
groups on the surface, or by co-condensation in a one-pot
synthesis; both methods are currently being discussed in view of
their advantages and disadvantages.14–17 The different modifica-
tions can be used to optimize the amount of drug taken up and
delivered by mesoporous silica-based drug delivery systems.
Furthermore, they can influence the kinetics of drug release. A
variety of modifications is possible. For example, a hydrophobic
character can be imparted to the silica surface by the attachment
of unreactive groups (e.g. trimethylsilyl18–20). In addition,This journal is ª The Royal Society of Chemistry 2011
Fig. 1 Scheme showing the different materials used in this study. Different modifications were carried out to achieve a high loading and a controlled
release of ciprofloxacin from mesoporous silica films. Glass substrates were functionalized successively with a mesoporous silica film (sample A), by the
introduction of sulfonic acid groups (sample B), by loading with ciprofloxacin (sample C), by the application of a surface layer derived from bis-
(trimethoxysilyl)hexane by dip-coating (sample D), and by the additional application of a surface layer derived from dioctyltetramethyldisilazane by
evaporation coating (sample E).
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View Article Onlinenegatively charged groups (like carboxyl21,22), positively charged
ones (as protonated amino groups16,17,23) or reactive groups (as
epoxy24 or thiol residues25) can be used to tailor the surfaceThis journal is ª The Royal Society of Chemistry 2011properties in order to match the properties of the drug to be
delivered. The density of these functionalities has to be adjusted
carefully. Especially in the attachment of charged groups, the netJ. Mater. Chem., 2011, 21, 752–760 | 753
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View Article Onlinecharge of the surface is a crucial factor, where also the unreacted
silanol groups retain their influence.26 For example, the loading
of a drug consisting of negatively charged molecules can be
enhanced when positive charges are placed on the surface,23,27,28
drug molecules with extended hydrophobic parts can be attrac-
ted to the surface by the presence of hydrophobic residues.18,29
The release of a drug to an aqueous medium can be retarded by
a protective outer hydrophobic layer which hinders the
surrounding aqueous media from entering the pores.20,30
Here we report a practical approach for equipping implants
with the ability to fight bacterial infections by local delivery of
ciprofloxacin, a broad spectrum antibiotic, from a specially
developed mesoporous silica coating (see scheme in Fig. 1). Such
silica coatings can be applied to standard implant materials, e.g.
Bioverit II, a mica-containing glass ceramic from which
ossicular replacement prostheses and other implants are
routinely fabricated.31,32 We use a sulfonic acid modification to
increase the amount of loaded ciprofloxacin in a mesoporous
silica layer and show its biocompatibility and its effectiveness in
combating bacteria in vitro. Additional coatings generated from
silanes are added to attenuate the typical initial burst release
behavior of drug delivery systems and retard the delivery of the
drug.Experimental
Mesoporous silica layer
As base material for the coatings glass substrates (Glasbearbei-
tung Henneberg & Co., Martinroda, Germany) were used. The 3-
mercaptotrimethoxysilane, 1,3-di-n-octyltetramethyldisilazane
and the bis(trimethoxysilyl)hexane were ordered from ABCR
GmbH & Co. KG (Karlsruhe, Germany). Absolute ethanol was
purchased from Merck (Darmstadt, Germany). All other
chemicals were obtained from Sigma-Aldrich Chemie GmbH
(Munich, Germany). All chemicals were used without further
purification.
For the compilation of in vitro release profiles standard glass
slides (76 mm  26 mm) and for cell culture experiments glass
disks (10 mm 10 mm) with a height of 0.95 mm were employed.
In a further experiment, where we determined simultaneously the
release properties and the antibacterial efficacy, the release
profiles were also determined using the glass disks described. The
different substrates were first coated with mesoporous silica
layers. Prior to the coating, all specimens were cleaned in an
ultrasonic bath, first in absolute ethanol and then in acetone for
ten minutes each.
The solution used for the preparation of nanostructured silica
coatings contained ethanol, water, hydrochloric acid, tetrae-
thoxysilane (TEOS) as a silica source and poly(ethylene glycol)-
poly(propylene glycol)-block-co-polymer (Sigma-Aldrich,
EO20PO70EO20, average Mnz 5800, similar to Pluronic P-123,
BASF) as the structure-directing agent.33 The dip-coating solu-
tion had a molar composition of TEOS : EtOH : H2O :
HCl : EO20PO70EO20 ¼ 1 : 48.9 : 26.9 : 0.06 : 0.0135. It was
prepared by adding TEOS to EO20PO70EO20 dissolved in
a mixture of ethanol, water and hydrochloric acid; the solution
was stirred for about ten minutes before coating the specimens.
Glass samples were coated using a dip-coating procedure,754 | J. Mater. Chem., 2011, 21, 752–760employing a DC Small Dip-Coater with 75 mm travel from NIMA
(Coventry, England), operated in a climate box at a constant
humidity adjusted by 50% w/w glucose solution. The samples were
immersed in the coating solution and then withdrawn perpen-
dicular to the surface of the solution with a speed of approximately
1 mm min1. The samples were then left at constant humidity for
five minutes. After coating, the specimens were dried at 60 C
overnight, followed by calcination at 415 C for four hours (rate of
heating/cooling 1 C min1). This material, consisting of the
mesoporous silica layer only, is designated as ‘‘A’’ in Fig. 1 and in
the following.
Sulfonic acid modification
The sulfonic acid modification was carried out according to ref.
34. The following procedure was applied in parallel for five glass
slides. The glass slides were cooled to 0 C in 45 ml of
dichloromethane before 5.9 ml of 3-mercaptotrimethoxysilane
were added. The solution was gently stirred for 22 h without
renewing the ice bath. Then the glass slides were washed with
dichloromethane and absolute ethanol and dried at 100 C for
five hours. 50 ml of hydrogen peroxide (30% w/w) were added
and allowed to react for 48 h followed by washing with water and
absolute ethanol. Finally the glass slides were dried at 60 C for
two hours and cooled to room temperature before the insertion
of ciprofloxacin. This material, consisting of the sulfonate-
modified mesoporous layer, is designated as ‘‘B’’ in Fig. 1 and in
the following.
Drug loading procedure
The insertion of ciprofloxacin was carried out in a 60 mM
solution of the drug at pH 4 and at 37 C for three days, either
with samples presenting the unmodified mesoporous layer or the
sulfonate-modified one. The solution was prepared as follows:
10 g of ciprofloxacin were added to about 300 ml of water and the
pH value was decreased with hydrochloric acid (2 M) until a clear
yellow solution was formed (pHz 2). Then the pH was adjusted
to 4 with sodium hydroxide solution (1 M), thereby approaching
a volume of 500 ml. Finally the solution was supplemented to
500 ml.
After the insertion, the glass slides were rinsed with 50 ml of
water for each side to wash off the highly concentrated solution
at the outer surface of the glass slide. Afterwards the glass slides
were dried for two hours at room temperature at constant air
humidity adjusted with 50% w/w glucose. Then, these samples
were either transferred to the release experiment or modified
further as described below. The drug-loaded material based on
sulfonate-modified layer is referred to as ‘‘C’’ in Fig. 1 and in the
following.
Controlled release modifications
To produce a hydrophobic layer on the surface of the meso-
porous layer, it was treated with bis(trimethoxysilyl)hexane using
a dip-coating procedure, following ref. 30. For this purpose,
a solution containing 8.7 ml bis(trimethoxysilyl)hexane, 31.2 ml
ethanol, 1.29 ml water and 1.614 ml hydrochloric acid (0.1 M)
was stirred for 30 min. Glass slides were then dipped into the
solution individually and withdrawn with an approximate speedThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlineof 2 cm s1 to avoid leaching of the inserted ciprofloxacin. The
samples were dried for twelve hours at room temperature at
constant air humidity adjusted with 50% w/w glucose. Then, they
were either transferred to the release experiment or modified
further as described below. This material, consisting of the drug-
loaded sulfonate-modified mesoporous layer and the hydro-
phobizing silane-derived layer is referred to as ‘‘D’’ in Fig. 1 and
in the following.
For the further modification, samples of type D were treated
with dioctyltetramethyldisilazane (1,3-di-n-octyltetramethyl-dis-
ilazane) via the vapour phase. For this purpose, 6 ml of the
silazane were put into a 300 ml Erlenmeyer flask (broad-necked)
and heated to 52 C for ten hours. During this time, five samples
were hanging above the liquid at the upper end of the flask at
a distance of about 15 cm.20 After drying for ten minutes at
ambient conditions, the samples were transferred to the release
experiment. This material, based on material D, but carrying
another silazane-derived surface layer is referred to as ‘‘E’’ in
Fig. 1 and in the following.Ciprofloxacin release
The release measurements were conducted as follows: five glass
slides were placed into 45 ml of a pre-warmed solution (37 C) of
0.01 M phosphate buffered saline (PBS) and kept at this
temperature. The measurements of the ciprofloxacin concentra-
tion in the solution took place after fixed time intervals of 15, 35,
55, 75, 135, 195 and 315 min. Afterwards, the measurements were
performed every 24 h. The quantitative determination of cipro-
floxacin in the solution was carried out on a spectrophotometer
UV-mini 1240 (Shimadzu, Duisburg, Germany) at 275 nm. The
whole medium was replaced after each measurement to simulate
dynamic fluid conditions in the body.
In a further experiment, where we determined simultaneously
the release properties and the antibacterial efficacy, the release
profiles were determined on 10 mm  10 mm glass disks, similar
to those which were used in the bacteria culture experiment. The
samples were incubated in 0.5 ml PBS and the medium was
replaced every 48 h for a period of ten days. Blank values
determined on ciprofloxacin-free sulfonated mesoporous silica
substrates were subtracted.Biocompatibility testing
For biocompatibility testing, we studied the behavior of the
sulfonated base material (sample B) in comparison with cipro-
floxacin loaded materials (samples C, D and E). Samples were
transferred to a 24-well plate. The sulfonic acid modified surface
and cell culture plastic (CCP) were used as controls. Briefly,
a near confluent culture of NIH3T3 cells was detached with
trypsin and the resulting suspension was diluted to 1 : 5 in fresh
cell culture medium. One millilitre of this cell suspension was
added to each of the wells containing the glass disks. The disks
were incubated with these cells at 37 C in a cell culture incu-
bator. Images of the cells were taken with an Axio Observer.A1
microscope (Carl Zeiss, Oberkochen, Germany) at 24 and 72 h
intervals after inoculation of the cells. The experiment was
repeated three times. Additionally, corresponding ciprofloxacin-
free samples were tested as a control. Sample D withoutThis journal is ª The Royal Society of Chemistry 2011ciprofloxacin is assigned as F, sample E as G. Sample H is
equipped with the evaporation coating with dioctylte-
tramethyldisilazane applied on sample E, but without the
bis(trimethoxysilyl)hexane coating below.Antibacterial efficacy
For testing the efficacy of the different materials against bacteria,
glass disks with the mesoporous coating (sample A), with addi-
tional sulfonic acid modification (sample B) and with that same
material loaded with ciprofloxacin (sample C) were placed in
a 24-well plate. Plane glass disks were used as control. Each of
these disks was incubated with 100 ml of a bacterial suspension of
OD600 ¼ 0.2 of P. aeruginosa (PAO1 CTX::lux) in PBS for 15
min at room temperature. After 15 min, 0.9 ml of LB medium
(Luria Broth35) was added into each well and the multi-well plate
was placed on a shaker at 60 rpm at 37 C. The plate was
observed under the IVIS-200 (Xenogen Corp., Alameda, Can-
ada) after six hours and the luminescence was measured indi-
vidually for each well.
For the investigation of the long-term antimicrobial efficacy of
the coatings, samples of sulfonic acid-modified mesoporous silica
films containing ciprofloxacin (sample C), and corresponding
samples modified in addition by dip-coating with
bis(trimethoxysilyl)hexane (sample D) and furthermore by
evaporation coating with dioctyltetramethyldisilazane (sample
E) were used. Disks of each of these materials were placed in
0.5 ml of LB medium and the supernatant was replaced every
48 h up to ten days. The supernatants collected individually from
different samples and after different release periods were then
added to 10 ml of a suspension of P. aeruginosa (PAO1 CTX::lux)
at an OD600 of 0.2. 90 ml of each supernatant were used.
Immediately after the addition and after six hours at 37 C, the
luminescence of each well was determined to determine the
bacterial viability which is given relative to the value of cipro-
floxacin-free mesoporous silica, which was set to 1.0.Characterization methods
The mesostructured layers were investigated by X-ray diffraction
(XRD). The samples were measured on a Stoe q–q-diffractom-
eter (Darmstadt, Germany) in reflection geometry. A secondary
beam monochromator (graphite) was applied to produce Cu Ka
radiation. Krypton adsorption/desorption measurements were
performed at 77 K with an Autosorb-1-MP instrument (Quan-
tachrome Instruments, Boynton Beach, Florida, USA). The
analysis station was equipped with high-precision pressure
transducers to ensure a highly accurate determination of the
adsorbed amount. During the equilibration time the sample cell
was isolated to minimize the effective dead volume. The satura-
tion pressure p0 was given as 2.63 mm Hg (p0 of supercooled
Krypton). Measurements were performed in the relative pressure
range from 0.025 to 0.400. Before the measurement, the samples
were outgassed at 200 C for 24 hours. The relative pressure
range of p/p0 ¼ 0.05 to 0.30 was chosen to determine the specific
BET surface area SBET, Kr. Static contact angle measurements
were performed on a Surftens universal contact angle goniometer
(OEG, Frankfurt/Oder, Germany) with water as the probing
liquid. On every glass slide, the contact angle was measured atJ. Mater. Chem., 2011, 21, 752–760 | 755
Fig. 2 Static contact angle measurements on a cleaned glass substrate, equipped with a mesoporous silica layer (A), after modification with sulfonic acid
groups (B), covered with a dip-coated layer derived from bis(trimethoxysilyl)hexane (D), in addition covered with a layer obtained by evaporation
coating with dioctyltetramethyldisilazane (E).
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View Article Onlinefive different positions, all at least five millimetres away from the
edges of the glass slide, and a representative image was chosen.
The thickness of the mesoporous silica film was measured with
a stylus profiler DETAK6M from Veeco instruments Inc.
(Plainview, USA) with a force of 9 mg, duration of 100 seconds
and a length of 3000 mm per measurement. The quantification of
sulfonic acid residues was carried out by methylene blue
adsorption according to ref. 36. Unmodified and sulfonic acid-
modified mesoporous silica layers on glass substrates (26  10
mm) were each placed into 1.5 ml of a 0.03 mM solution of
methylene blue in 0.01 M hydrochloric acid. The amount of
adsorbed dye was determined by the difference of methylene blue
concentration after 12 h. The calculated value is a mean of nine
samples. The blank values determined on unmodified meso-
porous silica layers were subtracted.Fig. 3 Release profiles of ciprofloxacin-loaded mesoporous silica layers
on glass substrates (A + CFX) functionalized successively with sulfonic
acid groups (C), a dip-coated layer derived from bis(trimethoxy-
silyl)hexane (D) and a layer derived from dioctyltetramethyldisilazane
(E) by evaporation coating.Results and discussion
Characterization of the mesoporous silica layer
X-Ray diffraction measurements gave results similar to those as
described in detail elsewhere,37 thus confirming the presence of
the mesostructure. Further investigations with a profilometer
revealed that a silica film as produced by our method on a glass
slide has a layer thickness varying between 30 and 150 nm.
Sorption measurements revealed that the film has an inner
surface of 11.2 cm2 per cm2 of the substrate, which shows
a large increase of the surface area. A typical amount of sila-
nol groups of calcined mesoporous materials is two to four
silanol groups per nm2. This leads to a value of 2.2 to 4.5  1015
silanol groups per cm2 of the substrate. The experimental
quantification of the number of sulfonic acid residues was carried
out by methylene blue adsorption.36 This assay gives a value of
approx. 2.4  1015 sulfonic acid groups per cm2 of the substrate.
Thus, more than half of the silanol groups present were trans-
ferred into sulfonic acid groups.
The different surface modifications carried out during the
whole procedure were monitored by static contact angle
measurements. The results show drastic changes in surface
properties (Fig. 2). Initially, the hydrophilic surface of the mes-
oporous silica layer can be discerned from the decrease of the
contact angle from about 20 (Fig. 2, glass) for the cleaned glass
substrate to less than 5 for the mesoporous silica layer (Fig. 2,
sample A). After the first modification steps producing sulfonic
acid groups, the surface stays hydrophilic with only a slight
increase of the contact angle which remains below 5 (Fig. 2,
sample B). Although propyl groups are also introduced onto the
surface, the hydrophilic sulfonic acid groups seem to dominate756 | J. Mater. Chem., 2011, 21, 752–760the surface chemistry. After dip-coating with
bis(trimethoxysilyl)hexane, the surface exhibits hydrophobic
properties with contact angles between 50 and 55 (Fig. 2,
sample D). The contact angle increases further after the evapo-
ration coating with dioctyltetramethyldisilazane in the last step
(Fig. 2, sample E), yielding values of more than 90.Controlled release profiles
Spectrophotometric analyses of the PBS supernatants of the
various coatings yielded information about the release profiles of
differently functionalized mesoporous silica films (Fig. 3).
Released amounts of ciprofloxacin are given according to the
macroscopic surface of the substrate. From the unmodified
mesoporous silica layer loaded with ciprofloxacin, 0.2 mg cm2 of
the drug were released (Fig. 3, sample ‘‘A + CFX’’). Upon
modification with sulfonic acid groups, this value increased
nearly ten-fold to 1.9 mg cm2 (Fig. 3, sample C). The unmodified
as well as the modified mesoporous layer both showed a typical
initial burst release profile, where most of the drug was released
within the first few hours, with just small amounts being released
after the first 24 h. After twelve days, practically all the cipro-
floxacin, which can be released (after the maximum time of 63
days) from the sulfonate-modified layer, had been released.
However, the release profiles could be tailored by further func-
tionalization steps. Samples which were dip-coated withThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlinebis(trimethoxysilyl)hexane show a slower release (Fig. 3, sample
D). After the first twelve days, approx. 90% of the total amount
had been released. The release rate then decreases so that very
small doses are still obtained up to 31 days. With the additional
surface coating produced by the evaporation of dioctylte-
tramethyldisilazane on top of the sample, an even more pro-
longed release profile is established (Fig. 3, sample E). Here, after
twelve days less than 50% of the total amount was released. After
a small initial burst, a constant release rate was observed for
more than 30 days, followed by regular smaller doses up to 63
days. The surface coatings did not influence the total amount of
drug released, which in all cases was about 2 mg cm2 of cipro-
floxacin. This fact demonstrates that only very small amounts of
ciprofloxacin were lost during the additional functionalization
steps. This could be a critical issue especially in the case of the
dip-coating procedure where the drug-loaded sample is exposed
to an aqueous solution, as it is in the following release experi-
ments. A fast withdrawal speed of ca. 2 cm s1 was used in this
step to avoid leaching of the inserted ciprofloxacin.
The release profiles depicted in Fig. 3 all show different release
rates in different time regions. During the initial burst, sample C,
which carried only the sulfonate modification, discharged
approx. 95% of the total released amount, whereas the samples
which were coated lost only approx. 30%. The sample which
was equipped with the dip-coated layer produced from
bis(trimethoxysilyl)hexane only (sample D) showed a rather fast
release in the first ten days and then a slower one afterwards. The
behavior of sample E, which possesses an additional coating
produced from evaporation coating by dioctylte-
tramethyldisilazane, is similar, but the release rates are lower and
the change from medium to slow release occurs only after
approx. 30 days.Fig. 4 Microphotographic images of cultured NIH3T3 fibroblast cells
on modified mesoporous coatings taken after 24 h (day 1) and 72 h
(day 3). Cell culture plastic (CCP) was used as a control; (B) sulfonated
mesoporous silica films. Samples C, D and E were loaded with cipro-
floxacin; samples F, G and H were used as ciprofloxacin-free controls.
The films were further modified as follows: (D and F) dip-coated with
bis(trimethoxysilyl)hexane; (E and G) dip-coated with bis(trimethoxy-
silyl)hexane and evaporation-coated with dioctyltetramethyldisilazane;
(H) evaporation-coated with dioctyltetramethyldisilazane.Biocompatibility testing
For biocompatibility testing samples were investigated with a cell
assay using the murine fibroblast cell line NIH3T3. Results are
shown in Fig. 4 and 5. Samples were tested with (samples C, D,
and E) and without ciprofloxacin loading (samples B, F, G, and
H). Substrates coated with a mesoporous silica layer modified
with sulfonic acid groups (sample B) and also loaded with
ciprofloxacin (sample C) proved to be highly biocompatible in
cell culture assays. Microscopic examination revealed that the
cells could efficiently adhere and proliferate on the coating, even
on the one releasing the loaded ciprofloxacin. Samples contain-
ing ciprofloxacin which were coated with an additional hydro-
phobic layer prepared from bis(trimethoxysilyl)hexane (sample
D), and with an additional coating produced by evaporation of
dioctyltetramethyldisilazane (sample E), exhibited a somewhat
lesser degree of proliferation. Similarly, ciprofloxacin-free
silica films coated with additional silane-derived layers showed
reduced cell densities. Here the following samples were
investigated: sample F with a layer prepared from
bis(trimethoxysilyl)hexane, sample G with two layers, derived
from bis(trimethoxysilyl)hexane and subsequent dioctylte-
tramethyldisilazane evaporation, and sample H, coated only
using dioctyltetramethyldisilazane. Due to cracks appearing in
these organosilane-derived coatings during the cell culture
experiment and the hydrophobic nature of the surface, the cellsThis journal is ª The Royal Society of Chemistry 2011 J. Mater. Chem., 2011, 21, 752–760 | 757
Fig. 5 Biocompatibility of ciprofloxacin-loaded mesoporous coatings
inoculated with NIH3T3 fibroblast cells for 72 h (day 3) at 37 C. The cell
densities are given relative to the value of cells grown on cell culture
plastic which was set to 1 (CCP). Samples C, D and E were loaded with
ciprofloxacin; samples F, G and H were used as ciprofloxacin-free
controls. The films were further modified as follows: (D and F) dip-
coated with bis(trimethoxysilyl)hexane; (E and G) dip-coated with
bis(trimethoxysilyl)hexane and evaporation-coated with dioctylte-
tramethyldisilazane; (H) evaporation-coated with dioctylte-
tramethyldisilazane.
Fig. 6 Antibacterial efficacy of a ciprofloxacin-loaded mesoporous silica
film against luminescent bacteria (P. aeruginosa, PAO1 CTX::lux) after
6 h in vitro. (A) Mesoporous silica film on a glass substrate; (B) as A, but
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View Article Onlinewere not able to adhere well on the surface after one day of
incubation under cell culture conditions. After three days of
incubation this effect was reduced. Thus, whereas all samples can
be considered as biocompatible, this property is somewhat
compromised in the case of the silane-derived surface coatings.with sulfonic acid modification; (C) as B, but loaded with ciprofloxacin.
A plain glass sample (glass) is used as a reference and the radiance is given
relative to the value of this sample which was set to 1.Antibacterial efficacy
The bacteria of the P. aeruginosa stem used (PAO1 CTX::lux)
exhibit luminescence when alive. Results of experiments using
these bacteria illustrate the antibacterial efficiency of cipro-
floxacin-loaded samples. After six hours in LB medium, cipro-
floxacin-loaded samples showed only about one-eighth of the
bacterial luminescence in comparison to the values obtained with
the mesoporous silica coating only, with the sulfonate-func-
tionalized mesoporous silica and with a glass control (Fig. 6).
These results show that the amount of ciprofloxacin of the
delivery system is in principle appropriate to locally curb
bacterial proliferation.
To test the efficacy of the time-dependent release from func-
tionalized mesoporous silica films, we incubated disks of mate-
rials C, D and E (see Fig. 1) in LB medium and collected the
supernatants every 48 h up to ten days. The medium was replaced
each time after removing the supernatant liquid. These samples
collected were afterwards tested for their effect on the prolifer-
ation of the luminescent P. aeruginosa bacteria (i.e. in the absence
of the drug delivery systems). In parallel, the release of cipro-
floxacin was studied on an identical time-scale. For this purpose,
corresponding samples were placed in PBS buffer solution, and
the supernatant was collected and replaced every 48 h (due to the
high absorbance of the LB medium, it was not possible to
determine ciprofloxacin concentrations directly in this medium
using our method). In this way, it was possible to correlate the
amount of ciprofloxacin released and its effect on bacterial
population in a simulated dynamic fluid environment (Fig. 7).758 | J. Mater. Chem., 2011, 21, 752–760The sulfonated mesoporous film loaded with ciprofloxacin
(sample C in Fig. 7) released the antibiotic very fast in an initial
burst. In the supernatant collected after two days, no prolifera-
tion of bacteria was observed whereas at later time points, the
release of the residual minimal amounts of ciprofloxacin still
delivered by the porous film cannot hinder the bacteria from an
almost unrestricted proliferation of up to 90% of the control. The
functionalized mesoporous silica film equipped with a slow-
release layer derived from bis(trimethoxysilyl)hexane (sample D
in Fig. 7) shows no bacteria proliferation up to six days with
a following slow increase of bacterial viability up to 40% of the
control. This is consistent with the general release profile in vitro.
The proliferation rate in the supernatants of the LB medium of
silica coatings additionally functionalized by dioctylte-
tramethyldisilazane (sample E in Fig. 7) starts with 40% of the
control after two days and decreases to approximately 10% after
six days, followed by an increase up to 60% after ten days. This
behavior indicates that the amount of ciprofloxacin released
from these coatings is lower than that from the other samples,
but these reduced amounts can still suffice to have an effect on
bacterial growth. However, with this double silane-derived
coating, the bacterial population does not decrease to practically
zero at any point-of-time. The amounts of ciprofloxacin released
in PBS show the same trend, but the largest dose is released here
after eight days, somewhat later than in the LB mediumThis journal is ª The Royal Society of Chemistry 2011
Fig. 7 Release profiles (top) and antibacterial efficacy (bottom) of
ciprofloxacin loaded sulfonated mesoporous silica films. Sulfonated
mesoporous silica films on glass substrates consecutively functionalized
by loading with ciprofloxacin (C), by dip-coating with bis(trimethoxy-
silyl)hexane (D), and by evaporation coating with
This journal is ª The Royal Society of Chemistry 2011
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View Article Onlineexperiment. This reflects probably an effect of the different
incubation media on the release kinetics. Furthermore, subtle
differences in the handling or experimental procedures have to be
considered.
These investigations show that it is possible to suppress
bacterial proliferation for up to ten days by functionalized
mesoporous silica films loaded with ciprofloxacin. The strong
antibacterial activity of ciprofloxacin-loaded sulfonated meso-
porous silica layers indicates that this material represents
a promising practical approach to effectively fight bacterial
infections of implants with very high local drug concentrations
that would not be tolerable by systemic administration. The
release of the antibiotic can be successfully controlled by the
application of organosiloxane layers derived from
bis(trimethoxysilyl)hexane which also possess a sufficient
biocompatibility.30 According to our results, the additional
application of a layer derived from dioctyltetramethyldisilazane
appears to be less advisable, as the biocompatibility of such
a coating layer is somewhat compromised and the amounts of
ciprofloxacin released in a certain unit of time are quite low.
Conclusions
A general practical approach for the antibiotic defense directly
from implants is presented. A sulfonated mesoporous silica film
has a high loading capacity for the antibiotic ciprofloxacin.
Additional layers of bis(trimethoxysilyl)hexane or dioctylte-
tramethyldisilazane can be applied to delay the release and to
prolong the effective antibacterial activity period. Controlled
release profiles can therefore be tailored using a fast dip-coating
procedure, possibly in combination with an evaporation-coating
approach. The general biocompatibility for all samples was
demonstrated in cell culture experiments. Importantly, cells
could even directly adhere to the ciprofloxacin-loaded sulfonated
mesoporous silica films. The silane-derived surface coatings
somewhat compromised the biocompatibility of the surface
layers. Antibacterial efficacy was shown for a clinically relevant
period of up to ten days, using pathogenic biofilm-forming
bacteria. These results suggest that the development of drug-
loaded mesoporous silica films as coatings on medical implants is
a promising approach to prevent bacterial implant infections
during the most critical time span after implantation. The
materials described here are currently being tested in mice and
rabbit animal models, in the latter case with specific regard to
middle-ear implants.
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